• 

  FDA Head Calls for Investigation Into Controversial Aduhelm Approval
• 

  FDA Limits the Use of Aduhelm After Criticisms of Broad Approval
• 

  FDA Speeds Up Process for Two More Anti-Amyloids
• 

  The Questions Doctors Are Getting About Aduhelm Right Now—And Their Answers
• 

  Will Insurance Companies and Medicare Cover Aduhelm’s High Price Tag?
• 

  A Retired Neurologist On His Experience With Aduhelm’s Side Effects
• 

  Amyloid Hypothesis in the Hot Seat After Aduhelm Approved for Alzheimer’s
• 

  What is an Aduhelm Infusion, and Why Was Its Approval So Controversial?
• 

  What Is Aduhelm and How Does It Fight Alzheimer’s?
• 

  Phil’s Journal: Aduhelm Is Greenlit to Treat Alzheimer’s—It’s Still Complicated
• 

  Experts Respond to Aduhelm Approval
• 

  Aducanumab Approved: U.S. FDA Gives Biogen Alzheimer’s Drug Approval
• 

  Our Experience With Aduhelm: Inside the Clinical Trial
• 

  Phil’s Journal: What’s Next for the Aducanumab Clinical Trial Rollercoaster?
• 

  Q&A With Dr. Stephen Salloway: Implications of the FDA Aducanumab Decision

Previous234Next